Natural Solutions for Life Recalls Synodrin Pain Relieving Cream Due to Failure to Meet Child Resistant Closure Requirement

What was recalled

In late November 2017, the U.S. Consumer Product Safety Commission (CPSC) announced a significant recall involving a popular over-the-counter topical pain reliever manufactured by Natural Solutions for Life. The specific item at the center of this safety notice is the Synodrin Lidocaine Maximum Strength Pain Relieving Cream. This product is designed to provide temporary relief from minor aches and pains associated with backaches, muscle strains, bruises, arthritis, and simple sprains. However, the scope of this recall is precise and limited to specific batches of this cream that failed to meet federal safety packaging standards. It is important for consumers to understand exactly which version of the product is affected, as not all Synodrin products or future iterations may carry the same packaging defect.

The recalled items are distinct in their physical appearance, making them identifiable even if you have forgotten the exact date of purchase. These jars of pain relieving cream come packaged in a white plastic jar with a blue label. The front of the jar clearly displays the text "Synodrin Lidocaine Maximum Strength 4% Pain Relieving Cream" in legible lettering. Each individual jar measures approximately three inches in diameter and stands about three inches tall, containing roughly four ounces of the cream. This specific sizing is crucial for identification, as smaller or larger jars from other Synodrin lines are not part of this recall.

Furthermore, these jars were not sold individually but were housed within a specific outer box to aid in retail display and consumer recognition. The outer packaging is a blue box featuring prominent yellow letters that spell out "Lidocaine" along with white letters indicating "Maximum Strength 4% Pain Relieving Cream." The brand name Synodrin is printed on both the jar itself and the exterior of the box, ensuring brand visibility. To help retailers and consumers track inventory, the right side of both the box and the jar bears the Universal Product Code (UPC) number 8 64751 00032 6. If you do not see this specific UPC code on the side of your packaging, your product is likely not part of this specific recall lot.

While the CPSC announcement did not specify the exact total number of units sold nationwide, it noted that these products were distributed widely to retailers across the United States. The lack of a precise unit count in the public record suggests that the volume was significant enough to warrant federal attention due to the potential danger posed to young children. The recall was officially initiated on November 30, 2017, meaning any Synodrin cream purchased prior to or after this date could potentially be included if it matches the physical description and UPC code detailed above. Consumers are urged to check their medicine cabinets carefully against these specific visual and numerical identifiers to determine if they possess the recalled item.

The hazard, explained

At the heart of this recall is a seemingly minor packaging flaw that carries significant potential for serious harm. The United States Consumer Product Safety Commission (CPSC) initiated this action because the Synodrin pain relieving cream fails to meet the mandatory child-resistant closure requirements set forth in the Poison Prevention Packaging Act. To understand why this matters, it helps to look at what those regulations are designed to do and how a standard lid falls short of that goal.

Child-resistant packaging is not designed to be impossible for adults to open; rather, it is engineered to be difficult enough to deter young children from accessing the contents. These specialized containers typically require a specific combination of actions—such as pushing down while twisting, squeezing sides together, or aligning arrows—that develop only after years of motor skill development and cognitive understanding. The recalled Synodrin jars, however, use standard lids that can be opened with simple pulling or unscrewing motions. A toddler or young child, who possesses the strength to twist a jar but lacks the judgment to understand danger, can easily open this container. Once the seal is broken, the lid offers no further barrier to entry.

The danger lies in what is inside that accessible jar: lidocaine. Lidocaine is a local anesthetic commonly used to numb pain, but it is also a potent drug that affects the central nervous system. When ingested by a young child, even a small amount can be toxic. Children have smaller body masses and developing metabolisms, meaning their bodies process drugs differently than adults. A dose that might cause mild drowsiness in an adult could lead to severe poisoning in a child.

Poisoning from lidocaine ingestion can manifest quickly and dangerously. Symptoms may include dizziness, confusion, seizures, difficulty breathing, and changes in heart rate. Because the packaging does not prevent access, the risk is not theoretical; it is an immediate physical possibility whenever the jar is left within reach. The hazard is compounded by the fact that pain relieving creams often have scents or textures that might intrigue a child, increasing the likelihood of accidental ingestion. While no incidents have been reported to date with this specific batch, the mechanism of harm is clear: inadequate packaging allows access to a substance that requires strict medical supervision for safe use.

It is important to distinguish between the product’s efficacy and its safety profile. The cream itself functions as intended for pain relief, but the failure here is entirely in the delivery system. The Poison Prevention Packaging Act exists precisely because manufacturers must ensure that potentially harmful substances are locked behind barriers that align with a child’s developmental limitations. By failing this standard, the Synodrin packaging transforms a useful medical product into an accessible hazard.

This type of regulatory violation highlights why government oversight is critical in consumer goods. While most users will never encounter a problem, the margin for error with chemicals like lidocaine is virtually zero when it comes to young children. The "how" of the injury is straightforward: easy-open lid plus accessible jar equals potential ingestion. The "why" is that the current packaging does not meet the federal safety threshold designed to prevent exactly this scenario.

Who is most at risk

While this recall affects anyone who purchased the specific jars of Synodrin Pain Relieving Cream, the individuals facing the most immediate and severe danger are young children, particularly those under the age of five. The core issue here is not the cream itself being inherently toxic in small amounts, but rather the accessibility of a concentrated medication due to packaging that fails to meet federal safety standards. Young children are naturally curious explorers who learn about their world by putting objects in their mouths. A white jar with a blue label and bright yellow lettering on the box can look like a toy or a treat to a toddler. Because the packaging does not have a child-resistant closure, it is far too easy for a small hand to twist open or pull off the lid, granting them direct access to the contents.

The specific risk comes from the active ingredient, lidocaine, which is a local anesthetic used to numb pain. While safe for adults when used as directed on intact skin, lidocaine can be highly dangerous if ingested by a child. A small child’s body mass is significantly lower than that of an adult, meaning even a small amount of the cream—perhaps just a mouthful or two—can lead to a much higher concentration of the drug in their bloodstream. This can result in lidocaine poisoning, which affects the central nervous system. Symptoms can range from mild dizziness and nausea to more serious conditions such as seizures, irregular heartbeat, and difficulty breathing. Because children cannot always articulate that they feel dizzy or nauseous, parents might not realize the severity of the situation until it escalates.

Additionally, households with elderly individuals may also be at heightened risk, though for slightly different reasons. Seniors often manage multiple medications and may have reduced dexterity or vision. They might mistakenly leave the jar within easy reach after use, assuming it is safe because it is a "topical" product. If an elderly person with cognitive decline were to ingest the cream thinking it is a topical ointment for themselves, the consequences could be equally severe. The lack of a child-resistant cap means that even if the jar is placed on a low shelf or in a bathroom cabinet without a lock, it remains vulnerable to being grabbed by anyone with limited motor skills or cognitive awareness.

It is important to note that while the recall notice states no incidents have been reported yet, the potential for harm exists solely because of the packaging failure. The hazard is not that the cream has changed composition or become contaminated; it is that the barrier protecting consumers from accidental ingestion is missing. Therefore, the "at risk" group is defined by access and vulnerability: anyone in a home where young children can reach the item, or where individuals might inadvertently consume topical products, is in the danger zone until the free replacement cap is installed.

How to tell if you have the recalled item

Before you take any action, the most critical step is confirming whether the jar of cream in your bathroom cabinet or medicine drawer matches the specific products involved in this recall. Because the issue stems from a packaging defect rather than the chemical composition of the medication itself, visual inspection is your primary tool for identification. You do not need to open the container to verify its status; in fact, it is safer to leave it sealed until you have arranged for the proper remedy.

Start by examining the jar itself. The recalled Synodrin Lidocaine Maximum Strength Pain Relieving Cream comes in a distinct white jar that stands approximately three inches tall and measures about three inches in diameter. It weighs roughly four ounces when full. The most noticeable feature is the label, which is blue and prominently displays the text "Synodrin Lidocaine Maximum Strength 4% Pain Relieving Cream" on the front. If your jar is white but has a different label color or lacks this specific blue branding, it is likely not part of this recall.

Next, look at the outer packaging, if you still have the box. The recalled items were sold in blue boxes featuring yellow letters that spell out "Lidocaine" and white letters indicating "Maximum Strength 4% Pain Relieving Cream." Ensure that the brand name Synodrin is clearly printed on both the jar and the box. This combination of a blue box with specific yellow and white typography is a key identifier for this batch.

To be absolutely certain, check the right side of both the jar and the box for the Universal Product Code (UPC). The recalled items bear the UPC code 8 64751 00032 6. If this number is present, you have one of the affected products. If the code is different, or if the product was purchased in a different size, color scheme, or formulation, it is not included in this specific safety notice. If you are unsure, comparing your item directly against these detailed physical descriptions will provide clarity.

• Jar Color: White
• Label Color: Blue with white and yellow text specifics
• Dimensions: Approximately 3 inches in diameter and height
• Weight: Approximately 4 ounces
• UPC Code: 8 64751 00032 6 (on the right side of jar and box)

What to do — step by step

Your refund, repair, or replacement options

If you have recently purchased Synodrin Lidocaine Maximum Strength Pain Relieving Cream and are worried about the safety of the packaging, take a moment to breathe. The good news is that the remedy for this specific recall is straightforward, accessible, and designed to resolve the issue without costing you anything out of pocket. Because the hazard stems from the container’s inability to protect children from accidental ingestion rather than a defect in the cream itself, the manufacturer has opted to provide a physical solution—a free replacement cap—rather than a monetary refund or a full product exchange. This approach is both practical and environmentally considerate, as it addresses the root cause of the safety failure while allowing you to continue using a product that may otherwise be effective for your needs.

To obtain your free replacement cap, you will need to reach out to Natural Solutions for Life directly. They have established a dedicated toll-free number for this purpose: 855-499-6435. When you call, please note that their support team is available from 9 a.m. to 5 p.m. Eastern Time, Monday through Friday. It is helpful to have your product on hand before you dial, as having the UPC code (8 64751 00032 6) ready can help them verify that your item is indeed part of this specific recall batch. If you prefer not to call, you can also submit your request online. Simply visit www.Synodrin.com and navigate through their website by clicking on “About Us” and then selecting “Recall Information.” This digital pathway is designed to be intuitive, ensuring that you can secure your remedy even if phone lines are busy during peak hours.

You might wonder why the remedy is limited to a cap rather than a full refund. In recalls involving child-resistant closure failures, the primary legal and safety obligation is to eliminate the risk of poisoning. Since the cream itself remains chemically stable and safe when stored in an appropriate container, providing a compliant, child-resistant cap restores the product to its legally required safety standard. This means you do not need to throw away your entire jar of cream, which can be a relief for those who have already begun using it. Once you receive the new cap, simply screw it onto your existing jar tightly and securely. This action effectively neutralizes the hazard by ensuring that young children cannot easily open the container.

While waiting for your replacement cap to arrive, please remember that safety is the immediate priority. Do not leave the current jar within reach of children, even if you believe they are too young to open it. Toddlers are surprisingly dexterous, and the lack of a child-resistant closure on this specific batch poses a genuine risk of lidocaine poisoning. By following these steps, you are not only complying with federal safety guidelines but also ensuring that your household remains protected while maintaining access to the pain relief product you may rely on.

What can happen if you ignore it

It is completely understandable why you might hesitate to act on a recall notice that seems technical or minor. After all, the packaging failure here is not about the cream itself being defective or contaminated; it is about the seal. When you see a notification about a "child-resistant closure," it can feel like a bureaucratic hurdle rather than an urgent safety mandate. However, ignoring this specific issue carries real, tangible risks that go far beyond simple inconvenience. The core danger lies in the disconnect between the product’s potency and its accessibility. Synodrin is a maximum strength pain relieving cream containing 4% lidocaine. While lidocaine is a widely used and generally safe local anesthetic for adults when applied correctly, it is not candy, and it is certainly not safe for unsupervised access by young children.

Lidocaine works by blocking nerve signals in the body. In small, controlled doses, this provides effective pain relief. However, if a child manages to open the jar due to the non-compliant cap and ingests even a small amount of the cream, the consequences can be severe. Children’s bodies are significantly smaller than adults’, meaning their weight-to-volume ratio makes them far more susceptible to toxic effects from medications that might be harmless to an adult. The primary risk here is systemic poisoning. If absorbed in significant quantities, lidocaine can affect the central nervous system and the heart. Symptoms of such poisoning can include dizziness, confusion, seizures, irregular heartbeats, and in worst-case scenarios, respiratory failure or cardiac arrest.

You might wonder why there are no reported incidents listed for this recall. The absence of reported injuries is actually a testament to luck rather than safety. It means that, so far, no families have been caught off guard by this specific flaw resulting in harm. But relying on the hope that "nothing happened yet" is a dangerous gamble. The hazard is latent and ever-present as long as the non-child-resistant cap remains in place. Every time a child reaches for a jar they see on a counter or nightstand, the probability of an accidental exposure increases. There is no warning sign when a toddler decides to taste something new; they do not read labels or understand warnings.

Furthermore, ignoring the recall denies you the simple remedy that has already been prepared for you. The manufacturer is offering free replacement caps, which instantly restores the safety barrier intended by law. By doing nothing, you are choosing to maintain a preventable risk when the solution is just a phone call or a website click away. The peace of mind that comes from knowing your home is truly safe from accidental poisoning far outweighs the minor effort required to secure these jars. Do not wait for a scare to realize that this packaging flaw was a ticking clock, not a trivial detail.

Staying safe: broader tips